[Chronic delay of growth with normal response of XXXX secretion to provocation stimuli for its liberation and decreased somatomedin activity: treatment with @entity2124 over 6 months].

@entity1 @entity1169 @entity851 @entity4053 @entity2124 @entity25
Four prepuberal @entity1 , two @entity1 and two @entity1 , aged 7 years 3 months to 11 years 6 months with chronic @entity851 were studied. Informed parental consent was obtained. Growth was followed for two years or more and was always less than P 3. Growth velocity during observation period was 4 cm/y or less. Gastrointestinal, hepatic, renal and thyroid functions were normal. Skeletal X-ray examination revealed no anomalies. karyotype in the two @entity1 was 44XX. @entity2124 ( @entity2124 ) secretion was evaluated in all cases by two different test: exercise- @entity1169 and insulin-induced @entity4053 . Peaks of @entity2124 secretion were 10 ng/ml or more. In three @entity1 , @entity2124 secretion was also evaluated during first two hours of @entity25 . @entity2124 peaks were 10, 4 and 13.4 ng/ml, respectively. Somatomedin activity (SA) measured in basal condition on two different days with six month interval was low (0.28-0.70 U/ml) and increased after seven daily doses of 2 mg of @entity2124 , in all @entity1 (0.80-1.12 U/ml). All @entity1 were treated with @entity2124 (2 mg/3 times/week), and growth velocity increased from 4 to 8.7, from 3.9 to 8.8, from 3 to 6.5 and from 3.2 to 6 cm/y, respectively. In conclusion, SA is of value in selection of @entity1 with chronic @entity851 , who may benefit from long-term @entity2124 therapy.
